Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF
Circulation: Heart Failure · 2026
DOI: 10.1161/circheartfailure.125.013201 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Heart Failure, 2026. Verfasst von Jawad H Butt und 23 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.H.B., A.D.H., P.S.J., M.C.P., J.J.V.M.). Hauptthemen laut MEDLINE: Bilirubin, Heart Failure, Liver Diseases, Mineralocorticoid Receptor Antagonists. Die Arbeit nennt 34 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: The prevalence and prognostic significance of liver biomarkers in heart failure (HF) with mildly reduced or preserved ejection fraction are uncertain, with both potential hemodynamic and metabolic contributions to liver dysfunction in these patients. We evaluated the prevalence and prognostic value of liver biomarkers and assessed the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone on these biomarkers and clinical outcomes in FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure). METHODS: FINEARTS-HF was a randomized, double-blind, placebo-controlled trial that enrolled 6001 patients with left ventricular ejection fraction ≥40%, evidence of structural heart disease, and elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels. Liver biomarkers examined were total bilirubin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase. RESULTS: Among 5873 patients with available baseline bilirubin measurements, 11.9% had elevated levels (>1.0 mg/dL). Higher bilirubin levels were associated with a greater risk of total worsening HF events and cardiovascular death. Compared with placebo, finerenone rapidly reduced bilirubin and alkaline phosphatase levels (but not transaminase levels), with effects sustained over time. Finerenone reduced the risk of total worsening HF events and cardiovascular death across all bilirubin tertiles (T1 [
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.H.B., A.D.H., P.S.J., M.C.P., J.J.V.M.).
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.L.C., A.S.D., M.V., S.D.S.).
- Bayer, Research & Development, Pharmaceuticals, Whippany, NJ (M.B., Y.D.S.).
- Bayer AG, Global Medical Affairs, Berlin, Germany (K.R., R.D.).
- Children's University Hospital (KUNO), University Hospital Regensburg, Germany (R.D.).
- National Heart Centre Singapore & Duke-National University of Singapore (C.S.P.L.).
ORCID-Profile: Alasdair D Henderson, Pardeep S Jhund, Brian L Claggett, Akshay S Desai, Rania Dayoub, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Johann Bauersachs, Cândida Fonseca, Gerard C M Linssen, Mark C Petrie, Morten Schou, Subodh Verma, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D Solomon, John J V McMurray
Zitieren
APA
Butt, J. H., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Borentain, M., Rohwedder, K., Dayoub, R., De Sanctis, Y., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Bauersachs, J., Fonseca, C., Linssen, G. C. M., Petrie, M. C., Schou, M., Verma, S., …, & McMurray, J. J. V. (2026). Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.125.013201
Vancouver
Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, et al. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. Circulation: Heart Failure. 2026. doi:10.1161/circheartfailure.125.013201
BibTeX
@article{Butt2026,
author = {Butt, Jawad H and Henderson, Alasdair D and Jhund, Pardeep S and Claggett, Brian L and Desai, Akshay S and Borentain, Maria and Rohwedder, Katja and Dayoub, Rania and De Sanctis, Yoriko and Lam, Carolyn S P and Senni, Michele and Shah, Sanjiv J and Voors, Adriaan A and Bauersachs, Johann and Fonseca, Cândida and Linssen, Gerard C M and Petrie, Mark C and Schou, Morten and Verma, Subodh and Zannad, Faiez and Pitt, Bertram and Vaduganathan, Muthiah and Solomon, Scott D and McMurray, John J V},
title = {Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF},
journal = {Circulation: Heart Failure},
year = {2026},
doi = {10.1161/circheartfailure.125.013201}
}
EUVIMED